Claims
- 1. A method for the treatment of patients with chronic bronchitis comprising administering to the patient a dry powder or nebulized aerosol formulation comprising from about 1 to about 500 mg of an aminoglycoside antibiotic once or twice daily for at least five days.
- 2. The method of claim 1 wherein the amino glycoside antibiotic is selected from the group consisting of gentamycin, amikacin, kanamycin, streptomycin, neomycin, netilmicin and tobramycin.
- 3. The method in claim 2 wherein the amino glycoside antibiotic is gentamycin.
- 4. The method in claim 2 wherein the amino glycoside antibiotic is amikacin.
- 5. The method in claim 2 wherein the amino glycoside antibiotic is kanamycin.
- 6. The method in claim 2 wherein the amino glycoside antibiotic is streptomycin.
- 7. The method in claim 2 wherein the amino glycoside antibiotic is neomycin.
- 8. The method in claim 2 wherein the amino glycoside antibiotic is netilmicin.
- 9. The method in claim 2 wherein the amino glycoside antibiotic is tobramycin.
- 10. The method in claim 1 wherein the antibiotic is administered in an aerosol or in a dry powder form.
- 11. The method in claim 10 wherein the antibiotic is administered in an aerosol form.
- 12. The method of claim 11 wherein the aerosol is delivered by a jet ultrasonic or electronic nebulizer.
- 13. The method in claim 11 wherein the antibiotic is administered in a formulation that upon aerosolization has particle sizes between about 1 and 5 microns.
- 14. The method in claim 10 wherein the antibiotic is administered in a dry powder form.
- 15. The method of claim 14 wherein the dry powder is delivered by a dry powder inhaler or by a metered dose inhaler.
- 16. The method in claim 12 wherein the dry powder has particle sizes between about 1 and 5 microns.
- 17. The method in claim 10 wherein the antibiotic is administered in a formulation have a pH between about 5.5 and 6.5.
- 18. A method of claim 1 wherein from about 1 to 400 mg of the antibiotic is administered twice daily for at least five days.
- 19. A method of claim 18 wherein from about 100 to 400 mg of tobramycin is administered twice daily for at least five days.
- 20. A method in claim 19 wherein from about 250 to about 350 mg of tobramycin is administered twice daily for at least five days.
- 21. A method in claim 19 wherein about 300 mg of tobramycin is administered twice daily for at least five days.
- 22. A method for the treatment of bronchitis comprising administering to patient in need of such treatment an endobronchial formulation comprising about 250 to about 350 mg of tobramycin dissolved in about 5 ml of solution containing a quarter normal saline adjusted to pH between about 5.5 and 6.5 and administered by nebulization using an ultrasonic nebulizer able to produce predominantly aerosol particle sizes between 1 and 5 microns.
Parent Case Info
This application is a 371 of PCT/US99/30234 filed Dec. 17, 1999which claims benefit of U.S. Provisional Application No. 60/112,984 filed Dec. 17, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US99/30235 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/35461 |
6/22/2000 |
WO |
A |
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5141674 |
Leigh |
Aug 1992 |
A |
5512269 |
Vedia et al. |
Apr 1996 |
A |
5522385 |
Lloyd et al. |
Jun 1996 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/112984 |
Dec 1998 |
US |